Ukawa Shigekazu, Nakamura Koshi, Okada Emiko, Hirata Makoto, Nagai Akiko, Yamagata Zentaro, Muto Kaori, Matsuda Koichi, Ninomiya Toshiharu, Kiyohara Yutaka, Kamatani Yoichiro, Kubo Michiaki, Nakamura Yusuke, Tamakoshi Akiko
Department of Public Health, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
J Epidemiol. 2017 Mar;27(3S):S65-S70. doi: 10.1016/j.je.2016.12.008. Epub 2017 Feb 17.
Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project.
Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated.
Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing.
We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.
在日本，前列腺癌是癌症相关死亡的第六大主要原因。我们旨在阐明日本生物样本库（BBJ）项目中前列腺癌患者的临床和组织病理学特征。
纳入了BBJ项目中4793例被诊断为前列腺癌的患者。分析了包括死亡原因在内的临床和组织病理学数据。计算了前列腺癌的相对生存率（RS）。
4171例有可用组织学数据的前列腺癌患者患有腺癌。患者的平均年龄为72.5岁。不吸烟、不饮酒、体重指数正常、不运动、前列腺特异性抗原水平正常以及有前列腺癌家族史的患者比例分别为30.7%、28.0%、66.6%、58.1%、67.6%和6.5%。II期、III期和IV期疾病患者的比例分别为24.4%、7.3%和4.4%。将范围限制在从前列腺癌初始诊断到进入研究队列的时间≤90天的患者（n = 869）后，5年和10年RS率分别为96.3%和100.5%，尽管由于大量数据缺失我们无法考虑管理策略。
我们提供了BBJ项目中前列腺癌患者的概况。我们的研究结果，与来自各种高通量“组学”技术的结果相结合，将有助于实施前列腺癌患者的预防干预措施和医疗管理。
